ARCT · Healthcare
Arcturus Therapeutics Holdings
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$231M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About ARCTURUS THERAPEUTICS HOLDINGS
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA…
Who's behind the signal
Every informed buyer we can see on ARCT, across all three feeds.
Hedge funds · 6
Citadel Advisors
New position
ARK Invest (Cathie Wood)
Increased +6%
D.E. Shaw & Co
Increased +158%
AQR Capital Management
Increased +272%
Millennium Management (Englander)
Increased +57%
Point72 (Steve Cohen)
Decreased −71%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ARCTURUS THERAPEUTICS HOLDINGS isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
4
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Citadel Advisors's portfolio
Trust weight: 1.3×
% of portfolio
0.2%
Position change
+6%
0.2% of ARK Invest's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+158%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+272%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+57%
0.0% of Millennium Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−71%
0.0% of Point72's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ARCTURUS THERAPEUTICS HOLDINGS
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ARCTURUS THERAPEUTICS HOLDINGS or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订